Gilead stuffs an­oth­er NASH drug dis­cov­ery pro­gram in­to a grow­ing port­fo­lio

When Daniel O’Day shows up for work as the new CEO of Gilead $GILD lat­er this year, he’ll in­her­it a bustling R&D op­er­a­tion cen­tered on its ex­per­i­men­tal drugs for NASH. 

Their late-stage re­veal on selon­sert­ib — along with a sim­i­lar un­veil­ing from In­ter­cept — is one of the most an­tic­i­pat­ed events of the year. And Gilead has two oth­er mid-stage drugs in the pipeline to help build what it hopes will be an in­dus­try-lead­ing cock­tail for NASH, much like they did for HIV and he­pati­tis C. Those 3 clin­i­cal drugs make up half of the 6 drugs Gilead lists in its pipeline for liv­er dis­eases, in­clud­ing he­pati­tis B.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.